---
title: Oral Vitamin D2 for Prevention of COVID-19
nct_id: NCT05673980
overall_status: UNKNOWN
phase: NA
sponsor: Peking University Third Hospital
study_type: INTERVENTIONAL
primary_condition: Healthy Volunteers
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05673980.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05673980"
ct_last_update_post_date: 2023-01-06
last_seen_at: "2026-05-12T06:12:36.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Oral Vitamin D2 for Prevention of COVID-19

**Official Title:** A Randomized Controlled Clinical Trial of Oral Vitamin D2 for the Prevention of COVID-19

**NCT ID:** [NCT05673980](https://clinicaltrials.gov/study/NCT05673980)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 218
- **Lead Sponsor:** Peking University Third Hospital
- **Collaborators:** Beijing Haidian Hospital
- **Conditions:** Healthy Volunteers
- **Start Date:** 2022-12-18
- **Completion Date:** 2023-02-20
- **CT.gov Last Update:** 2023-01-06

## Brief Summary

A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks.

## Detailed Description

This study is a randomized controlled multicenter clinical trial. Participants who meet the inclusion criteria can be included in this trial after signing informed consent. A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks. Throughout the trial, participants' nucleic acid or antigen results, 25(OH)D concentrations, etc., need to be tested.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Willing to participate in the clinical study and sign the informed consent;
2. Staff members of Peking University Third Hospital, including the hospital headquarters, Capital International Airport Hospital, North Hospital, Beijing Haidian Hospital, Peking University Third Hospital Yanqing Hospital and Peking University Third Hospital Chongli Hospital;
3. Test negative for COVID-19 antigen and have no symptoms related to COVID-19.

Exclusion Criteria:

1. Hospital staff with serious underlying diseases;
2. Pregnant and lactating women;
3. Long-term vegetarians;
4. Long-term chronic diarrhea, history of subtotal gastrectomy, biliary obstructive disease and pancreatic disease.
```

## Arms

- **vitamin D2** (EXPERIMENTAL) — Oral dose of Vitamin D2 every two weeks
- **Placebo** (PLACEBO_COMPARATOR) — Without any intervention

## Interventions

- **Vitamin D2** (DRUG) — Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
- **placebo** (OTHER) — This group will not do any intervention

## Primary Outcomes

- **Change in incidence of laboratory-confirmed (or COVID-19 antibody test) COVID-19 infection** _(time frame: 4 weeks)_ — The test will be nucleic acid or antigen testing twice a week for four weeks

## Secondary Outcomes

- **The duration of a positive to negative antigen test after infection with COVID-19** _(time frame: up to 4 weeks)_
- **The duration of symptoms in COVID-19 positive participants** _(time frame: up to 4 weeks)_
- **The proportion of participants whose symptoms of COVID-19 infection were confirmed by antigen testing for more than 7 days** _(time frame: 4 weeks)_
- **The proportion of asymptomatic COVID-19 infected persons (those who test positive for the etiology of COVID-19 but have no related clinical manifestations)** _(time frame: 4 weeks)_

## Locations (1)

- Peking University Third Hospital, Beijing, Beijing Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.peking university third hospital|beijing|beijing municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05673980.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05673980*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*